Discovering new antimicrobial agents.
暂无分享,去创建一个
[1] Zhong Chen,et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. , 1999, Science.
[2] R. Breaker,et al. Antibacterial lysine analogs that target lysine riboswitches. , 2007, Nature chemical biology.
[3] T. Louie,et al. OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection , 2008, Antimicrobial Agents and Chemotherapy.
[4] V. Saba,et al. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. , 2003, The Journal of infectious diseases.
[5] W. Shi,et al. Systematic Approach to Optimizing Specifically Targeted Antimicrobial Peptides against Streptococcus mutans , 2010, Antimicrobial Agents and Chemotherapy.
[6] K. LaPlante,et al. Telavancin: a novel lipoglycopeptide antimicrobial agent. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[7] J. Koehn,et al. N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity , 2002, Antimicrobial Agents and Chemotherapy.
[8] M. Mammen,et al. Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II , 2009, Antimicrobial Agents and Chemotherapy.
[9] R. J. Doerksen,et al. Nontoxic membrane-active antimicrobial arylamide oligomers. , 2004, Angewandte Chemie.
[10] Alexis Criscuolo,et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. , 2010, The Journal of infectious diseases.
[11] R. Moellering. Rationale for use of antimicrobial combinations. , 1983, The American journal of medicine.
[12] M. Zervos,et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] T. Pruett. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .
[14] A. So,et al. Tackling antibiotic resistance , 2010, BMJ : British Medical Journal.
[15] D. Bertrand,et al. Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors , 2010, Antimicrobial Agents and Chemotherapy.
[16] Timothy R. Walsh,et al. Tackling antibiotic resistance , 2011, Nature Reviews Microbiology.
[17] K. Krause,et al. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. , 2010, The Journal of antimicrobial chemotherapy.
[18] Martha S. Head,et al. Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents , 2002, Antimicrobial Agents and Chemotherapy.
[19] G. Bammert,et al. Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.
[20] O. Levy. A Neutrophil-Derived Anti-Infective Molecule: Bactericidal/Permeability-Increasing Protein , 2000, Antimicrobial Agents and Chemotherapy.
[21] G. Talbot,et al. In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States , 2008, Antimicrobial Agents and Chemotherapy.
[22] J. Lipuma,et al. In Vitro Activities of a Novel Nanoemulsion against Burkholderia and Other Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species , 2008, Antimicrobial Agents and Chemotherapy.
[23] P. Silley,et al. Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system , 1990, Antimicrobial Agents and Chemotherapy.
[24] D. Skow,et al. Antibacterial Activity and Mechanism of Action of a Novel Anilinouracil-Fluoroquinolone Hybrid Compound , 2007, Antimicrobial Agents and Chemotherapy.
[25] Gracia Morales,et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] D. Nicolau,et al. In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance , 2009, Antimicrobial Agents and Chemotherapy.
[27] C. Mant,et al. Role of Peptide Hydrophobicity in the Mechanism of Action of α-Helical Antimicrobial Peptides , 2006, Antimicrobial Agents and Chemotherapy.
[28] Chad W. Euler,et al. Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.
[29] D. Shlaes,et al. The pleuromutilin antibiotics: a new class for human use. , 2010, Current opinion in investigational drugs.
[30] R. Hancock. Peptide antibiotics , 1997, The Lancet.
[31] T. Nicas,et al. Mechanism of action of oritavancin and related glycopeptide antibiotics. , 2003, FEMS microbiology reviews.
[32] A. Fothergill,et al. NB-002, a Novel Nanoemulsion with Broad Antifungal Activity against Dermatophytes, Other Filamentous Fungi, and Candida albicans , 2009, Antimicrobial Agents and Chemotherapy.
[33] S. Bhavnani,et al. Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia , 2009, Antimicrobial Agents and Chemotherapy.
[34] R. Flamm,et al. In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms , 2004, Antimicrobial Agents and Chemotherapy.
[35] M. Page,et al. In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli , 2010, Antimicrobial Agents and Chemotherapy.
[36] I. Chopra,et al. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. , 2010, The Journal of antimicrobial chemotherapy.
[37] P. Charifson,et al. Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds , 2006, Antimicrobial Agents and Chemotherapy.
[38] Angela Lee,et al. Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy , 2001, Antimicrobial Agents and Chemotherapy.
[39] J. Fox. The business of developing antibacterials , 2006, Nature Biotechnology.
[40] Robert E W Hancock,et al. Effects of Hydrophobicity on the Antifungal Activity of α‐Helical Antimicrobial Peptides , 2008, Chemical biology & drug design.
[41] V. Fischetti,et al. Reinventing phage therapy: are the parts greater than the sum? , 2006, Nature Biotechnology.
[42] R. Breaker. RNA Second Messengers and Riboswitches: Relics from the RNA World?: Some riboswitches and their ligands may be relics of signaling networks used when organisms relied on RNA instead of DNA and proteins , 2010 .
[43] R. Moellering. Can the third-generation cephalosporins eliminate the need for antimicrobial combinations? , 1985, The American journal of medicine.
[44] N. Georgopapadakou,et al. Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli , 1993, Antimicrobial Agents and Chemotherapy.
[45] N. Curtis,et al. Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins , 1988, Antimicrobial Agents and Chemotherapy.
[46] U. Theuretzbacher,et al. Future antibiotics scenarios: is the tide starting to turn? , 2009, International journal of antimicrobial agents.
[47] G. Igrejas,et al. In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals. , 2010, Journal of Antimicrobial Chemotherapy.
[48] J. Garnacho-Montero,et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] H. Sahl,et al. New insights into the mechanism of action of lantibiotics--diverse biological effects by binding to the same molecular target. , 2000, The Journal of antimicrobial chemotherapy.
[50] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[51] Phil Barton,et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial , 2000, The Lancet.
[52] G. Vovis,et al. Genomics and Antimicrobial Drug Discovery , 1999, Antimicrobial Agents and Chemotherapy.
[53] D. Stevens,et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. , 2007, The Journal of infectious diseases.
[54] T. Stachyra,et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor , 2004 .
[55] D. Pritchard,et al. Quorum sensing: a novel target for anti-infective therapy. , 1998, The Journal of antimicrobial chemotherapy.
[56] J. Mond,et al. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. , 2007, The Journal of antimicrobial chemotherapy.
[57] G. Zurenko,et al. In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent , 2009, Antimicrobial Agents and Chemotherapy.
[58] Brad Spellberg,et al. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] D. Sahm,et al. Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates , 2009, Antimicrobial Agents and Chemotherapy.
[60] R. Bonomo,et al. Three Decades of β-Lactamase Inhibitors , 2010, Clinical Microbiology Reviews.